Loading
Life sciences · Journal article
European Journal of Translational Myology · August 6, 2026
Raises a question worth testing. It does not answer one.
This narrative review examines cannabidiol (CBD) as a potential modulator of skeletal muscle insulin resistance through anti-inflammatory and antioxidant pathways. Preclinical evidence is promising, but human clinical studies are limited and inconsistent; the authors conclude CBD is biologically plausible but clinically unproven and should be considered experimental, not established therapy.
Narrative review. Review addresses skeletal muscle physiology in obesity, type 2 diabetes, metabolic syndrome, and metabolic dysfunction-associated steatotic liver disease; human clinical evidence base not quantified. Intervention: Cannabidiol (CBD) as a modulator of skeletal muscle insulin resistance.
Preclinical data suggest CBD may influence pathways in skeletal muscle insulin resistance including chronic low-grade inflammation, oxidative stress, lipotoxicity, and ceramide accumulation Current human studies do not demonstrate consistent improvements in glycemic control or insulin sensitivity with CBD alone Evidence regarding CBD effects on muscle function, exercise performance, or rehabilitation outcomes is lacking
Preclinical data suggest CBD may influence pathways in skeletal muscle insulin resistance including chronic low-grade inflammation, oxidative stress, lipotoxicity, and ceramide accumulation
Clinicians should not adopt CBD as an established therapy for insulin resistance or muscle dysfunction. Current evidence warrants continued preclinical and human research, but does not support clinical use outside experimental trials.
A narrative review synthesizing preclinical and limited clinical evidence; concludes CBD is biologically plausible but clinically unproven, with no consistent human data supporting efficacy for insulin sensitivity or muscle function.
As stated by the source record.
Clinicians should not adopt CBD as an established therapy for insulin resistance or muscle dysfunction. Current evidence warrants continued preclinical and human research, but does not support clinical use outside experimental trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Insulin Resistance (IR) is a central pathophysiological mechanism underlying obesity, type 2 diabetes mellitus, metabolic syndrome, and metabolic dysfunction-associated steatotic liver disease, with significant implications for skeletal muscle function, exercise capacity, and rehabilitation outcomes. Because skeletal muscle represents the primary site of insulin-stimulated glucose disposal, muscle insulin resistance is a key determinant of both metabolic health and physical performance. Cannabidiol (CBD), a non-intoxicating phytocannabinoid derived from Cannabis sativa, has attracted increasing scientific interest due to its anti-inflammatory, antioxidant, and pleiotropic signaling properties. This narrative review aims to examine the relationship between CBD and insulin resistance, with a particular focus on skeletal muscle biology and its relevance for exercise and rehabilitation medicine. A structured literature search was conducted using major biomedical databases, including PubMed, Scopus, and Web of Science, to identify relevant preclinical and clinical studies. Evidence was synthesized narratively, with emphasis on skeletal muscle insulin resistance, endocannabinoid system signaling, potential mechanisms of CBD action, and clinical outcomes. Preclinical data suggest that CBD may influence several pathways involved in skeletal muscle insulin resistance, including chronic low-grade inflammation, oxidative stress, lipotoxicity, and ceramide accumulation. However, current human studies remain limited and do not demonstrate consistent improvements in glycemic control or insulin sensitivity with CBD alone. Furthermore, evidence regarding its effects on muscle function, exercise performance, or rehabilitation outcomes is lacking. In conclusion, CBD represents a biologically plausible but clinically unproven modulator of skeletal muscle insulin resistance. At present, it should be considered an experimental adjunct rather than an established therapeutic strategy. Future research should focus on well-designed clinical trials integrating metabolic and functional endpoints to determine its potential role alongside exercise-based interventions in rehabilitation medicine.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.